Mycobacterium chelonae infection associated with adalimumab therapy

Scandinavian Journal of Rheumatology

Volumn 37, Issue 2, 2008, Pages 159-160

  Diaz F ^a   Urkijo, J C ^a   Mendoza, F ^a   De La Viuda, J M ^a   Blanco, M ^a   Unzurrunzaga, A ^a   Ayarza, R ^a  

^a HOSPITAL DE GALDAKAO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AURAMINE; CLARITHROMYCIN; GOLD SALT; LEFLUNOMIDE; METHOTREXATE; PREDNISONE; RHODAMINE;

ACID FAST BACTERIUM; AGED; BACTERIUM CULTURE; CASE REPORT; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; LETTER; LIVER TOXICITY; MYCOBACTERIOSIS; MYCOBACTERIUM CHELONEI; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SKIN BIOPSY; SKIN EXAMINATION; SUBCUTANEOUS NODULE;

AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; MYCOBACTERIUM CHELONAE; MYCOBACTERIUM INFECTIONS, ATYPICAL; OPPORTUNISTIC INFECTIONS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 42149107529     PISSN: 03009742     EISSN: 15027732     Source Type: Journal    
DOI: 10.1080/03009740701716876     Document Type: Letter

References (10)

1. Strangfeld A, Listing J. Bacterial and opportunistic infections during anti-TNF therapy. Best Pract Res Clin Rheumatol 2006;20:1181-95.
2. Saliu OY, Sofer C, Stein DS, Schwander SK, Wallis RS. Tumor-necrosis-factor blockers: differential effects on mycobacterial immunity. J Infect Dis 2006;194:486-92.
3. Virginia-Pérez M, Abud-Mendoza C, Portillo-Salazar H, Alvarado-Sánchez B, Cuevas-Orta E, Moreno-Valdés R, et al. Immune effects of therapy with adalimumab in patients with rheumatoid arthritis. Clin Exp Immunol 2005;141:372-80.
4. Mufti AH, Toye BW, Mckendry RRJ, Angel JB. Mycobacterium abscessus infection after use of tumor necrosis factor α inhibitor therapy: case report and review of infectious complications associated with tumor necrosis factor α inhibitor use. Diag Microbiol Infect Dis 2005;53:233-8.
5. Yim K, Nazeer SH, Kiska D, Rose FB, Brown D, Cynamon MH. Recurrent Mycobacterium xenopi infection in a patient with rheumatoid arthritis receiving etanercept. Scand J Infect Dis 2004;36:150-3.
6. Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention or nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007;175:367-416.
7. Dinarello CA. Anti-cytokine therapeutics and infections. Vaccine 2003;21(Suppl 2):24-34.
8. Jacobs M, Togbe D, Fremond C, Samarina A, Allie N, Botha T, et al. Tumor necrosis factor is critical to control tuberculosis infection. Microbes Infect 2007;9:623-8.
9. Wallace RJ Jr, Brown BA, Onyi GO. Skin, soft tissue, and bone infections due to Mycobacterium chelonae chelonae: importance of prior corticosteroid therapy, frequency of disseminated infections, and resistance to oral antimicrobials other than clarithromycin. J Infect Dis 1992;166:405-12.
10. Wallace RJ, Tanner D, Brennan PJ, Brown BA. Clinical trial of clarithromycin for cutaneous (disseminated) infection due to Mycobacterium chelonae. Ann Int Med 1993;119:482-6.